Format

Send to

Choose Destination
Anticancer Res. 2018 Sep;38(9):5357-5361. doi: 10.21873/anticanres.12864.

Evaluation of the Prognostic Stage in the 8th Edition of the American Joint Committee on Cancer in Patients with Breast Cancer and Internal Mammary Lymph Node Metastasis.

Author information

1
Department of Radiation Oncology, Ajou University School of Medicine, Suwon, Republic of Korea.
2
Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea watermountain@hanmail.net.
3
Department of Breast and Endocrine Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
4
Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Abstract

BACKGROUND/AIM:

This study evaluated the prognostic value of the 8th edition of American Joint Committee on Cancer (AJCC) cancer staging system for patients with internal mammary lymph node (IMN) metastases.

MATERIALS AND METHODS:

Of the patients with breast cancer who were treated between 2009 and 2013, 66 were diagnosed as cN3b. We restaged the patients and analyzed the prognostic value of the prognostically staged groups.

RESULTS:

With a median follow-up of 53.9 months, the 5-year overall survival rates of patients with IIIA, IIIB, and IIIC stages were 100%, 95%, and 50% (p=0.001), while the progression-free survival rates were 100%, 83%, and 50% (p=0.005).

CONCLUSION:

Despite the small number of patients, the prognostic stage provided accurate information for IMN metastasized breast cancer, which will lead to more accurate prognosis predictions and optimal treatment selection.

KEYWORDS:

AJCC cancer staging; Breast neoplasms; internal mammary lymph nodes; neoplasm metastases; survival

PMID:
30194189
DOI:
10.21873/anticanres.12864
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center